BioSpace News Archive

Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”) announced today the closing of its previously announced underwritten public offering of 69,000,000 shares of its common stock, at a public offering price of $1.50 per share.

More than 40 leading ophthalmologists, vision researchers, and public health/policy experts are sharing data and holding discussions on the global burden of diabetes-related eye disease to develop a plan to address this leading cause of blindness at the 2nd Mexico-U.S. Symposium on Vision Health.

Precigen, Inc. (Nasdaq: PGEN) announced today the closing of its previously announced underwritten public offering of common stock.

Gilead Sciences, Inc. announced that its executives will be speaking at the following investor conferences: SVB Securities Global Biopharma Conference on Tuesday, February 14 at 11:20 AM Eastern Time Cowen Annual Health Care Conference on Tuesday, March 7 at 11:10 AM Eastern Time Barclays Global Healthcare Conference on Wednesday, March 15 at 10:15 AM Eastern Time The live webcasts can be accessed at the company’s investors page at investors.gilead.com.

Sensient Technologies Corporation will hold its conference call to discuss 2022 fourth quarter and year-end results at 8:30 a.m. CST on Friday, February 10, 2023.

Asep Medical Holdings Inc. is pleased to announce that it has signed a joint venture term sheet with a leading Chinese medical diagnostic company, Sansure Biotech Inc.

HuidaGene Therapeutics announces that the US. Food and Drug Administration has cleared its investigational new drug application for the planned multi-national clinical trial of HG004 for the treatment of patients suffering from RPE65 mutation-associated inherited retinal dystrophies, a group of genetic diseases caused by the mutations in RPE65 gene affecting the retina and passed on to the children.

Senti Biosciences, Inc. announced a strategic plan to focus internal resources on SENTI-202, SENTI-401 and, with potential partners, to continue to pursue the development of Gene Circuits for other programs, including solid tumors.

Qlaris Bio, Inc., a biotechnology company targeting high unmet needs in debilitating ophthalmic diseases, announced today that Thurein Htoo, MS, MBA, the company’s co-founder and chief executive officer, will present during the 12th Annual Glaucoma 360 New Horizons Forum on Friday, Feb. 3, 2023, at 8:40 a.m. PT (11:40 a.m. ET) in San Francisco.

BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, announced today that Lourdes Felix, Chief Executive Officer, Chief Financial Officer, and Director of BioCorRx, and Brady Granier, President and Director of BioCorRx, will be presenting virtually at the Sequire Biotechnology Conference.